AB0476 The Results of Total Hip Prosthesis in Rheumatoid Arthritis Patients

Objectives To review the results of total hip prosthesis in rheumatoid arthritis patients according to baseline disease activity Methods Total hip prosthesis was used on 36 RA patients (32 women, 4 men) with a mean age of 49,5±15,82 years. Disease duration at the time of surgery was 12,45±5,53 years. High disease activity by DAS28 was observed in 10 patients (27.8%), moderate - in 19 (52.8%), low - in 7 (19.4%) patients, the mean DAS28 4,5±1,7. At the time of surgery (before and after), 24 (66.7%) of the patients continued to take basic anti-rheumatic drugs (DMARDs) - (methotrexate 7.5-15 mg per week -15, leflunomide - 7, sulfasalazine - 2). 6 (16.6%) patients received biological therapy: infliximab - 2, adalimumab -1, rituximab - 3, which were canceled before the operation in accordance with the terms specified in the national guidelines. 19 (52.8%) patients received steroids, of which, in combination with DMARDs - 7 (19.4%). Before the surgery, in the postoperative period and after 6 months joint pain on a visual analogue scale (VAS), the activity of the disease - DAS28, functional capacity index HAQ have been evaluated Results For 6 months after surgery VAS decreased by 2.5 times to 31,7±19,4 mm (p